NDAINTRAVENOUSPOWDER
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
6/8 — Strong
BYFAVO (remimazolam besylate) by Acacia Pharma is benzodiazepine. Approved for sedation, mechanical ventilation. First approved in 2020.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYFAVO (remimazolam besylate) is an intravenous benzodiazepine that binds to GABA-A receptors in the brain to produce rapid sedation. It is indicated for procedural sedation and sedation of mechanically ventilated patients in critical care settings. The drug's active metabolite (CNS7054) has 300-fold lower receptor affinity, supporting faster offset and recovery compared to traditional benzodiazepines.
Peak7.7 years to LOE
BYFAVO is in peak commercial phase with strong patent protection through 2034, suggesting sustained investment in field teams and account management roles.
Mechanism of Action
benzodiazepine. BYFAVO binds to brain benzodiazepine sites (gamma amino butyric acid type A [GABA A ] receptors), while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. BYFAVO, like other benzodiazepines, did not show clear selectivity between subtypes of…
Indications (2)
Worked on BYFAVO at Acacia Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.